Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing
Supports Clinical and Commercial Supply Needs for Pompe and Other Lysosomal Disease Gene Therapy Programs Advances Amicus’ Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J. , July 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc.
View HTML
Toggle Summary Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration
         Supports Clinical and Commercial Supply Needs for Multiple Batten Disease Programs Advances Amicus Mission to Deliver Novel Gene Therapies to Rare Disease Patients CRANBURY, N.J. , July 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (NASDAQ:FOLD) has entered into a strategic
View HTML
Toggle Summary Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership
Jill Weimer , PhD named Senior Vice President of Discovery Research and Gene Therapy Science Simon Jordan named Senior Vice President of International CRANBURY, N.J. , June 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced two new additions to the Senior Leadership
View HTML
Toggle Summary Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J. , June 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 18,720,930 shares of its common stock, including 2,441,860 shares of common stock sold pursuant to
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences
CRANBURY, N.J. , June 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following scientific and investor conferences in June. Upcoming Scientific Conference : Michael C. Diem , MD, Senior Vice President of Business and Corporate
View HTML
Toggle Summary Amicus Therapeutics Prices Underwritten Offering of Common Stock
CRANBURY, N.J. , May 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross proceeds from the offering to Amicus are expected to be $175 million , before
View HTML
Toggle Summary Amicus Therapeutics Announces Public Offering of Common Stock
CRANBURY, N.J. , May 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock.  J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC are acting as joint book-running managers
View HTML
Toggle Summary Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration
Exclusive Disease-Specific Worldwide Rights to Penn’s Next Generation Gene Therapy Technologies from the Wilson Lab for the Majority of Lysosomal Disorders              Current Collaboration Extended to Include Three New Indications: Niemann-Pick Type C (NPC), Mucopolysaccharidosis Type IIIA (MPS
View HTML
Toggle Summary Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
CRANBURY, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment of Burke W. Whitman to its Board of Directors, effective at the end of this quarter. Mr. Whitman is a proven leader of corporate and military organizations.  He has
View HTML
Toggle Summary Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
CRANBURY, N.J. , May 10, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV on Tuesday, May 14,
View HTML